FDA Ongoing Review of Savara's Lung Disease Treatment Application, No Advisory Meeting Planned

Savara has announced that the FDA does not plan to convene an advisory committee to review its biologics license application for Molbreevi, a potential treatment for a lung disease. The FDA's review of the application is ongoing, targeting a decision date in Q4 2023. Savara's stock price fell following the announcement.